MDS Pharma Services Adopts SAS Technology for Clinical Trial Data Warehousing and Analysis
Innovative system gives clients real-time access to data, offers secure data warehousing and expedites data set conversions for electronic regulatory submissions
MDS Pharma Services Adopts SAS(R) Technology for Clinical Trial Data Warehousing and Analysis
Innovative system gives clients real-time access to data, offers secure data warehousing and expedites data set conversions for electronic
regulatory submissions
KING OF PRUSSIA, PA, June 16 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has adopted the SAS(R) Drug Development tool to provide a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research data. SAS Drug Development technology is being implemented across MDS Pharma Services from the pre-clinical line of business through Phase IV to integrate worldwide work flows. It also expedites conversion of data sets into the format established by the Clinical Data Interchange Standards Consortium (CDISC) for electronic regulatory submissions.
"This powerful tool will significantly improve our internal operational efficiency and enhance our ability to provide quality, on-time service to clients at all phases of their drug development process," said MDS Pharma Services President David Spaight. "It allows clients to view their study data even as it is being updated, serves as a secure repository of legacy clinical trial data, and can convert that data into standard CDISC format for electronic submission to regulators as part of a New Drug Application."
With the SAS Drug Development system, MDS Pharma Services can offer medium to large pharmaceutical industry clients the ability to combine historical clinical trial data from a variety of sources and studies, convert it to a common format and analyze it to identify patient safety issues or new demographic groups with commercial potential. For biotech clients, this tool will enable the integration of all available trial datasets and their conversion into a unified data package for due diligence, subsequent licensing or joint venturing with a potential commercial development partner.
"Collaboration within the R&D process must include shared visibility to information," said Jason Burke, worldwide director of Health and Life Sciences at SAS. "The aggregation and analysis of standardized data across a compound's lifecycle establishes a foundation for improving pharmaceutical R&D, and organizations like MDS Pharma Services that can operationalize these improvements have a distinct competitive advantage."
SAS Drug Development provides a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research information. The solution enables life sciences organizations to get products to market faster by more effectively assessing the safety and efficacy of research compounds. The solution also facilitates collaboration across trials, phases and therapeutic areas.
About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at http://www.mdsps.com.
MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
SOURCE MDS Pharma Services
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
